跳至主要内容
临床试验/NCT01405131
NCT01405131撤回1 期

Phase 1, Open-label, Randomized, Single-dose, 2-treatment, 2 Period Crossover Bioequivalence Study Comparing Constituted Methylprednisolone Powder For Oral Suspension 4 Mg/ml To Methylprednisolone 32 Mg Tablet Under Fasted Conditions

Pfizer0 个研究点开始时间: 2012年1月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
撤回
发起方
Pfizer
主要终点
AUCinf (area under the concentration curve to infinity)

研究概览

简要总结

A study to determine whether a new formulation of methylprednisolone suspension is bioequivalent to methylprednisolone tablets.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
None

入排标准

年龄范围
21 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy male or female subjects between the ages of 21 and 55 years.
  • Body Mass Index (BMI) of 17.5 to 30.5 kg/m2 and a total body weight > 45 kg (99 lbs).

排除标准

  • Any condition possibly affecting drug absorption (eg, gastrectomy).
  • A positive urine drug screen

研究组 & 干预措施

methylprednisolone suspension

Experimental

干预措施: methylprednisolone (Drug)

methylprednisolone tablets

Active Comparator

干预措施: methylprednisolone (Drug)

结局指标

主要结局

AUCinf (area under the concentration curve to infinity)

时间窗: 0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose

Cmax (maximum concentration)

时间窗: 0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose

次要结局

  • AUC last (area under the concentration curve to last time point)(0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose)
  • Tmax (time at maximum concentration)(0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose)
  • Half-life(0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose)

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

相似试验

A Bioequivalence Study Comparing Methylprednisolone... | 临床试验